Please use this identifier to cite or link to this item: https://doi.org/10.3390/ph14090834
DC FieldValue
dc.titleA systematic review of the clinical use of gabapentin and pregabalin in bipolar disorder
dc.contributor.authorNg, Qin Xiang
dc.contributor.authorHan, Ming Xuan
dc.contributor.authorTeoh, Seth En
dc.contributor.authorYaow, Clyve Yu Leon
dc.contributor.authorLim, Yu Liang
dc.contributor.authorChee, Kuan Tsee
dc.date.accessioned2022-10-26T08:33:18Z
dc.date.available2022-10-26T08:33:18Z
dc.date.issued2021-08-24
dc.identifier.citationNg, Qin Xiang, Han, Ming Xuan, Teoh, Seth En, Yaow, Clyve Yu Leon, Lim, Yu Liang, Chee, Kuan Tsee (2021-08-24). A systematic review of the clinical use of gabapentin and pregabalin in bipolar disorder. Pharmaceuticals 14 (9) : 834. ScholarBank@NUS Repository. https://doi.org/10.3390/ph14090834
dc.identifier.issn1424-8247
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/233488
dc.description.abstractDespite its prevalence and disease burden, several chasms still exist with regard to the pharmacotherapy of bipolar disorder (BD). Polypharmacy is commonly encountered as a significant proportion of patients remain symptomatic, and the management of the depressive phase of the illness is a particular challenge. Gabapentin and pregabalin have often been prescribed off-label in spite of a paucity of evidence and clinical practice guidelines to support its use. This systematic review aimed to synthesize the available human clinical trials and inform evidence-based pharmacological approaches to BD management. A total of six randomized, controlled trials (RCTs) and 13 open-label trials involving the use of gabapentin and pregabalin in BD patients were reviewed. Overall, the studies show that gabapentin and its related drug pregabalin do not have significant clinical efficacy as either monotherapy or adjunctive therapy for BD. Gabapentin and pregabalin are probably ineffective for acute mania based on the findings of RCT, with only small open-label trials to support its potential adjunctive role. However, its effects on the long-term outcomes of BD remain to be elucidated. The evidence base was significantly limited by the generally small sample sizes and the trials also had heterogeneous designs and generally high risk of bias. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
dc.publisherMDPI
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScopus OA2021
dc.subjectBipolar disorder
dc.subjectGabapentin
dc.subjectGabapentinoids
dc.subjectPregabalin
dc.subjectPsychopharmacology
dc.typeReview
dc.contributor.departmentYONG LOO LIN SCHOOL OF MEDICINE
dc.description.doi10.3390/ph14090834
dc.description.sourcetitlePharmaceuticals
dc.description.volume14
dc.description.issue9
dc.description.page834
Appears in Collections:Students Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_ph14090834.pdf662.02 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons